BTK and Miyoshi myopathy: Since overexpression of BTK is present in 85% of MM cases, ibrutinib appears as a promising therapy for MM patients, and the roles of BTK in the development of bone resorption by osteoclasts, as well as in cell migration, are characteristics that support BTK’s research in the context of MM development [108,110,111,112,113].